Oxigene Inc (OXGN) 2.80 $OXGN
OXiGENE Announces Results of Promising Preclinical Studies at 2014 AACR Conference
GlobeNewswire - Mon Apr 07, 9:00AM CDT
OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, today announced results from three preclinical studies related to its ongoing research and development programs. The data are being presented this week at the Annual Meeting of the American Association for Cancer Research (AACR) in San Diego, California.
Top Gainers Updates -- Research on Sangamo BioSciences, Synthesis Energy Systems, OXiGENE, and Affymetrix
PR Newswire - Tue Apr 01, 8:08AM CDT
On Monday, March 31, 2014, the US markets saw a positive sentiment, as the NASDAQ Composite closed at 4,198.99, up 1.04%, the Dow Jones Industrial Average ended the session at 16,457.66, up 0.82% and the S&P 500 edged 0.79% higher to finish the trading session at 1,872.34. The gains were broad based as nine out of 10 sectors ended the session in positive. A number of stocks saw large movements, including Sangamo BioSciences Inc. (NASDAQ: SGMO), Synthesis Energy Systems Inc. (NASDAQ: SYMX), OXiGENE Inc. (NASDAQ: OXGN) and Affymetrix Inc. (NASDAQ: AFFX). Free technical research on SGMO, SYMX, OXGN and AFFX can be downloaded upon signing up at:
Celsius Holdings Inc.'s Stock Volume Falls amid Minimal News
ACCESSWIRE - Tue Apr 01, 8:01AM CDT
Boca Raton, Fla.-based beverage company Celsius Holdings Inc.'s (OTCPINK: CELH) stock volume was low Mar. 31, with just 8,555 shares changing hands, less than half its three-month average volume of 18,039.
OXiGENE Announces Presentation of Three Preclinical Abstracts at 2014 AACR Conference
GlobeNewswire - Thu Mar 27, 7:30AM CDT
OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, today announced that data from three studies related to its early stage scientific programs will be presented at the Annual Meeting of the American Association of Cancer Research (AACR) being held April 5-9, 2014 at the San Diego Convention Center in San Diego, CA.
3 Biotech Stocks Under $10 to Trade
at The Street - Wed Mar 26, 5:00AM CDT
Keep your eye on these under-$10 biotech stocks.
Biotech Stock Mailbag: Amarin, Cytrx, Sangamo and 'Story Stocks'
at The Street - Fri Mar 21, 6:00AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
OxiGene (OXGN) Marked As A Dead Cat Bounce Stock
at The Street - Wed Mar 19, 8:51AM CDT
Trade-Ideas LLC identified OxiGene (OXGN) as a "dead cat bounce" (down big yesterday but up big today) candidate
OXiGENE posts higher net loss of USD8.3m for 2013
M2 - Wed Mar 19, 5:47AM CDT
Biopharmaceutical company OXiGENE (NasdaqCM:OXGN) on Tuesday reported a net loss of USD8.3m for the year ended 31 December 2013.
OXiGENE Reports Full Year 2013 Financial Results
GlobeNewswire - Tue Mar 18, 3:00PM CDT
OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, reported financial results for the year ended December 31, 2013.
Technical Summary - Most Active Equities: Symantec, Mobile Telesystems, Allied Nevada Gold, and OXiGENE
PR Newswire - Fri Mar 14, 7:25AM CDT
The trading session on Thursday, March 13, 2014 ended on a lower note as the Dow Jones Industrial Average finished at 16,108.89, down 1.41% and the NASDAQ Composite closed at 4,260.42, down 1.46%. The S&P 500 finished the session 1.17% lower at 1,846.34. The losses were broad based as nine of ten sectors ended the session in negative. Investor-Edge.com looks at some of the equities which were most active during the session. These include Symantec Corp. (NASDAQ:SYMC), Mobile Telesystems OJSC (NYSE:MBT), Allied Nevada Gold Corp. (NYSE MKT:ANV), and OXiGENE Inc. (NASDAQ:OXGN). Free research on these four companies can be accessed at:
Investment Grants, Data Presentations, Clinical Study Results, and Collaborative Programs - Analyst Notes on UnitedHealth Group, Bristol-Myers Squibb, AbbVie, Cigna, and OXiGENE
PR Newswire - Fri Mar 14, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding UnitedHealth Group Incorporated (NYSE: UNH), Bristol-Myers Squibb Company (NYSE: BMY), AbbVie Inc. (NYSE: ABBV), Cigna Corporation (NYSE: CI), and OXiGENE, Inc. (NASDAQ: OXGN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
SmarTrend Watching for Potential Pullback in Shares of OXiGENE After 77.27% Gain
Comtex SmarTrend(R) - Wed Mar 12, 5:13PM CDT
OXiGENE (NASDAQ:OXGN) traded in a range yesterday that spanned from a low of $4.14 to a high of $5.40. Yesterday, the shares gained 77.3%, which took the trading range above the 3-day high of $2.45 on volume of 29.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Nasdaq stocks posting largest volume increases
AP - Wed Mar 12, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Most active Nasdaq-traded stocks
AP - Wed Mar 12, 5:02PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
Small-Cap Biotech on the Verge of a Breakout: ABIO
at The Street - Wed Mar 12, 12:43PM CDT
Here's how to trade Arca Biopharma.
Oxigene Surprises With Positive Ovarian Cancer Study Success
at The Street - Wed Mar 12, 5:00AM CDT
A combination of Oxigene's Zybrestat and Roche's Avastin delayed the regrowth of tumors in women with advanced ovarian cancer.
UPDATE -- OXiGENE Announces Positive Topline Results From Randomized Phase 2 Study GOG186I of ZYBRESTAT(R) in Combination With Avastin(R) for Recurrent Ovarian Cancer
GlobeNewswire - Tue Mar 11, 4:43PM CDT
OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, today announced positive results from a randomized Phase 2 clinical trial evaluating Avastin (bevacizumab) with or without ZYBRESTAT (fosbretabulin; CA4P) to treat patients with recurrent ovarian cancer. The study, known as Gynecologic Oncology Group protocol 186I, met its primary endpoint of a statistically significant increase in progression-free survival (p-value less than 0.05; hazard ratio 0.685) for the combination as compared to bevacizumab alone.
OXiGENE Announces Positive Topline Results From Randomized Phase 2 Study GOG186I of ZYBRESTAT(R) in Combination With Avastin(R) for Recurrent Ovarian Cancer
GlobeNewswire - Tue Mar 11, 2:36PM CDT
OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, today announced positive results from a randomized Phase 2 clinical trial evaluating Avastin (bevacizumab) with or without ZYBRESTAT (fosbretabulin; CA4P) to treat patients with recurrent ovarian cancer. The study, known as Gynecologic Oncology Group protocol 186I, met its primary endpoint of a statistically significant increase in progression-free survival (p < 0.05; hazard ratio 0.685) for the combination as compared to bevacizumab alone.
OXiGENE Announces Updated Time for Presentation at the ROTH Conference
GlobeNewswire - Tue Mar 11, 12:04PM CDT
OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that the company's presentation and webcast at the ROTH Capital Partners 26 Annual Growth Stock Conference will take place on Wednesday, March 12 at 9:30 a.m. PT at The Ritz Carlton Hotel in Dana Point California. Peter Langecker, M.D., PhD., Chief Executive Officer, will provide an update and corporate overview.
OXiGENE Announces Results of Promising Preclinical Studies at 2014 AACR Conference
GlobeNewswire - Mon Apr 07, 9:00AM CDT
OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, today announced results from three preclinical studies related to its ongoing research and development programs. The data are being presented this week at the Annual Meeting of the American Association for Cancer Research (AACR) in San Diego, California.
Top Gainers Updates -- Research on Sangamo BioSciences, Synthesis Energy Systems, OXiGENE, and Affymetrix
PR Newswire - Tue Apr 01, 8:08AM CDT
On Monday, March 31, 2014, the US markets saw a positive sentiment, as the NASDAQ Composite closed at 4,198.99, up 1.04%, the Dow Jones Industrial Average ended the session at 16,457.66, up 0.82% and the S&P 500 edged 0.79% higher to finish the trading session at 1,872.34. The gains were broad based as nine out of 10 sectors ended the session in positive. A number of stocks saw large movements, including Sangamo BioSciences Inc. (NASDAQ: SGMO), Synthesis Energy Systems Inc. (NASDAQ: SYMX), OXiGENE Inc. (NASDAQ: OXGN) and Affymetrix Inc. (NASDAQ: AFFX). Free technical research on SGMO, SYMX, OXGN and AFFX can be downloaded upon signing up at:
Celsius Holdings Inc.'s Stock Volume Falls amid Minimal News
ACCESSWIRE - Tue Apr 01, 8:01AM CDT
Boca Raton, Fla.-based beverage company Celsius Holdings Inc.'s (OTCPINK: CELH) stock volume was low Mar. 31, with just 8,555 shares changing hands, less than half its three-month average volume of 18,039.
OXiGENE Announces Presentation of Three Preclinical Abstracts at 2014 AACR Conference
GlobeNewswire - Thu Mar 27, 7:30AM CDT
OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, today announced that data from three studies related to its early stage scientific programs will be presented at the Annual Meeting of the American Association of Cancer Research (AACR) being held April 5-9, 2014 at the San Diego Convention Center in San Diego, CA.
3 Biotech Stocks Under $10 to Trade
at The Street - Wed Mar 26, 5:00AM CDT
Keep your eye on these under-$10 biotech stocks.
Biotech Stock Mailbag: Amarin, Cytrx, Sangamo and 'Story Stocks'
at The Street - Fri Mar 21, 6:00AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
OxiGene (OXGN) Marked As A Dead Cat Bounce Stock
at The Street - Wed Mar 19, 8:51AM CDT
Trade-Ideas LLC identified OxiGene (OXGN) as a "dead cat bounce" (down big yesterday but up big today) candidate
OXiGENE posts higher net loss of USD8.3m for 2013
M2 - Wed Mar 19, 5:47AM CDT
Biopharmaceutical company OXiGENE (NasdaqCM:OXGN) on Tuesday reported a net loss of USD8.3m for the year ended 31 December 2013.
OXiGENE Reports Full Year 2013 Financial Results
GlobeNewswire - Tue Mar 18, 3:00PM CDT
OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, reported financial results for the year ended December 31, 2013.
Technical Summary - Most Active Equities: Symantec, Mobile Telesystems, Allied Nevada Gold, and OXiGENE
PR Newswire - Fri Mar 14, 7:25AM CDT
The trading session on Thursday, March 13, 2014 ended on a lower note as the Dow Jones Industrial Average finished at 16,108.89, down 1.41% and the NASDAQ Composite closed at 4,260.42, down 1.46%. The S&P 500 finished the session 1.17% lower at 1,846.34. The losses were broad based as nine of ten sectors ended the session in negative. Investor-Edge.com looks at some of the equities which were most active during the session. These include Symantec Corp. (NASDAQ:SYMC), Mobile Telesystems OJSC (NYSE:MBT), Allied Nevada Gold Corp. (NYSE MKT:ANV), and OXiGENE Inc. (NASDAQ:OXGN). Free research on these four companies can be accessed at:
Investment Grants, Data Presentations, Clinical Study Results, and Collaborative Programs - Analyst Notes on UnitedHealth Group, Bristol-Myers Squibb, AbbVie, Cigna, and OXiGENE
PR Newswire - Fri Mar 14, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding UnitedHealth Group Incorporated (NYSE: UNH), Bristol-Myers Squibb Company (NYSE: BMY), AbbVie Inc. (NYSE: ABBV), Cigna Corporation (NYSE: CI), and OXiGENE, Inc. (NASDAQ: OXGN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
SmarTrend Watching for Potential Pullback in Shares of OXiGENE After 77.27% Gain
Comtex SmarTrend(R) - Wed Mar 12, 5:13PM CDT
OXiGENE (NASDAQ:OXGN) traded in a range yesterday that spanned from a low of $4.14 to a high of $5.40. Yesterday, the shares gained 77.3%, which took the trading range above the 3-day high of $2.45 on volume of 29.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Nasdaq stocks posting largest volume increases
AP - Wed Mar 12, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Most active Nasdaq-traded stocks
AP - Wed Mar 12, 5:02PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
Small-Cap Biotech on the Verge of a Breakout: ABIO
at The Street - Wed Mar 12, 12:43PM CDT
Here's how to trade Arca Biopharma.
Oxigene Surprises With Positive Ovarian Cancer Study Success
at The Street - Wed Mar 12, 5:00AM CDT
A combination of Oxigene's Zybrestat and Roche's Avastin delayed the regrowth of tumors in women with advanced ovarian cancer.
UPDATE -- OXiGENE Announces Positive Topline Results From Randomized Phase 2 Study GOG186I of ZYBRESTAT(R) in Combination With Avastin(R) for Recurrent Ovarian Cancer
GlobeNewswire - Tue Mar 11, 4:43PM CDT
OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, today announced positive results from a randomized Phase 2 clinical trial evaluating Avastin (bevacizumab) with or without ZYBRESTAT (fosbretabulin; CA4P) to treat patients with recurrent ovarian cancer. The study, known as Gynecologic Oncology Group protocol 186I, met its primary endpoint of a statistically significant increase in progression-free survival (p-value less than 0.05; hazard ratio 0.685) for the combination as compared to bevacizumab alone.
OXiGENE Announces Positive Topline Results From Randomized Phase 2 Study GOG186I of ZYBRESTAT(R) in Combination With Avastin(R) for Recurrent Ovarian Cancer
GlobeNewswire - Tue Mar 11, 2:36PM CDT
OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, today announced positive results from a randomized Phase 2 clinical trial evaluating Avastin (bevacizumab) with or without ZYBRESTAT (fosbretabulin; CA4P) to treat patients with recurrent ovarian cancer. The study, known as Gynecologic Oncology Group protocol 186I, met its primary endpoint of a statistically significant increase in progression-free survival (p < 0.05; hazard ratio 0.685) for the combination as compared to bevacizumab alone.
OXiGENE Announces Updated Time for Presentation at the ROTH Conference
GlobeNewswire - Tue Mar 11, 12:04PM CDT
OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that the company's presentation and webcast at the ROTH Capital Partners 26 Annual Growth Stock Conference will take place on Wednesday, March 12 at 9:30 a.m. PT at The Ritz Carlton Hotel in Dana Point California. Peter Langecker, M.D., PhD., Chief Executive Officer, will provide an update and corporate overview.
